- PMID: 36793224
- DOI: 10.1177/10499091231158388
Objective: Chronic pain is a major problem for patients with Charcot-Marie-Tooth (CMT) disease. This exploratory study examined patient reported efficacy of medical cannabis for pain management in this population.
Methods: Participants (N = 56; 71.4% female; Age = 48.9, SD = 14.6; 48.5% CMT1) were recruited though the Hereditary Neuropathy Foundation. The online survey contained 52 multiple choice questions about demographics, medical cannabis use, symptomology, efficacy, and adverse effects.
Results: Nearly all (90.9%) of respondents reported experiencing pain, including all (100%) females and 72.7% of males (chi-square P < .05) with 91.7% of respondents indicating cannabis provided at least 50% pain relief. The most frequent response was an 80% reduction in pain. Moreover, 80.0% of respondents reported using less opiates, 69% noted using less sleep medication, and 50.0% reported using less anxiety/antidepressant medications. Negative side effects were noted by 23.5% of respondents. However, almost all (91.7%) of that subgroup did not have plans to stop consuming cannabis. One-third (33.9%) possessed a medical cannabis certificate. Patient perceptions of their physicians’ attitudes regarding patient medical cannabis use greatly impacted whether respondents informed their providers of their usage.
Conclusion: The vast majority of patients with CMT reported that cannabis was effective to manage pain symptoms. These data support the need for prospective, randomized, controlled trials using standardized dosing protocols to further delineate and optimize the potential use of cannabis to treat pain related to CMT.
Keywords: Charcot Marie Tooth, cannabis, chronic pain, hereditary motor and sensory neuropathy, marijuana, neuropathic pain
Genetic epidemiology of Charcot-Marie-Tooth disease.Acta Neurol Scand Suppl. 2012;(193):iv-22. doi: 10.1111/ane.12013.PMID: 23106488
Prescription of Controlled Substances: Benefits and Risks.2022 Sep 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.PMID: 30726003 Free Books & Documents.
Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and systematic review.J Neurol. 2017 Aug;264(8):1655-1677. doi: 10.1007/s00415-017-8474-3. Epub 2017 Mar 31.PMID: 28364294 Review.
Sensory manifestations in Charcot-Marie-Tooth disease.J Peripher Nerv Syst. 2004 Mar;9(1):7-14. doi: 10.1111/j.1085-9489.2004.09103.x.PMID: 14871449
Charcot-Marie-Tooth Hereditary Neuropathy Overview.1998 Sep 28 [updated 2022 Sep 29]. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023.PMID: 20301532 Free Books & Documents. Review.